| Programme | Time (SGT) |
|---|---|
| Session 1: (Chair) Overview |
|
| Opening lecture: A need for Asian Consensus HBV Endpoint meeting Prof. Lim Seng Gee View Bio |
|
| a. Scope of the meeting and agenda items Prof. Lim Seng Gee View Bio |
|
| Session 2 Consensus Statement 1: Consensus On Cure Definitions Revisiting terminology for HBV endpoints for patients and clinical trials of treatments of CHB: partial cure, functional cure, occult HBV infection, virological cure and complete cure Chairs Chairs: Prof. Geoff Dusheiko View Bio & Dr. Rajneesh Kumar |
|
| a. HCC risk and HBV DNA vs HBsAg Levels Prof. Young-Suk Lim View Bio |
|
| b. Partial cure is it a useful endpoint? Prof. Maria Buti FerretView Bio |
|
| c. Definitions and outcomes of Occult HBV infection Prof. Massimo Levrero View Bio |
|
| d. Viral integration: what is important? New integrations or integration burden Prof. Thomas Tu View Bio |
|
| e. From functional cure to virological cure Prof. Lim Seng Gee View Bio |
|
| f. Consolidating nomenclature forum Panel members including Mr. Dee Lee,View Bio Prof. Philippa EasterbrookView Bio & Prof. Veronica Miller,View Bio Prof. Thomas Tu View Bio |
|
| g. Discussion | |
| Tea Break | |
| Session 3: Consensus Statement 2: Biomarkers In Clinical Studies Of CHB Chairs: Prof. Henry Chan View Bio &, Prof. Thomas Tu View Bio |
|
| (1) The role of evaluating the liver microenvironment in clinical trials of CHB | |
| a. What to measure in the liver microenvironment (Immunology) Dr. Nina LeBert View Bio |
|
| b. What to measure in the liver microenvironment (Virology) Prof. Massimo Levrero View Bio |
|
| c. HBV integration and its loss during functional cure Prof. Thomas Tu View Bio |
|
| d. FNA vs LBx and the utility of liver tissue in clinical trials Prof. Geoff Dusheiko View Bio |
|
| e. Discussion | |
| Session 3: (Continuation) Consensus Statement 2: Biomarkers In Clinical Studies |
|
| (2) Novel biomarkers in clinical trials and clinical practice | |
| a. Spectrum of HBV biomarkers and virological pathways Prof. Massimo Levrero View Bio |
|
| b. Utility of novel biomarkers in CHB management Dr. Lung Yi Mak View Bio |
|
| Tea Break | |
| Session 4: (Chair) Consensus Statement 3: The Role Of Existing Treatment Strategies In Functional Cure Existing treatment strategies including strategies for HBV cure Chairs: Prof. Maria Buti Ferret View Bio & Prof. Khin Maung Win |
|
| a. Is NUC therapy needed for new trials of CHB for functional cure? Prof. Norah Terrault View Bio |
|
| b. Long term outcomes of NUC therapy Prof. Wei Lai View Bio |
|
| c. The use of Peginterferon in CHB functional cure Prof. Lim Seng Gee View Bio |
|
| d. Stopping NUC therapy Prof. Henry Chan View Bio |
|
| e. Discussion | |
| End of Day 1 | |
Asian HBV/HDV Endpoints Consensus Meeting Scientific Programme 2025
August, 2025
22
August, 2025
23
| Programme | Time (SGT) |
|---|---|
| Session 5: (Chair) Consensus Statement 4: Novel Therapies For Functional Cure Novel therapeutics leading to functional cure – controversies Chair: Prof. Massimo Levrero View Bio & Prof. Seng Gee Lim View Bio |
|
| b. ASO RNA therapeutics state of the art Prof. MF Yuen View Bio |
|
| c. RNA interference combination therapy Dr. Lung Yi Mak View Bio |
|
| d. Current Immunotherapy current prospects for functional cure Prof. Antonio Bertoletti View Bio |
|
| e. Gene therapy and prospects for HBV complete cure Prof. Ed Gane View Bio |
|
| f. Discussion | |
| Morning Tea Symposium sponsored by Roche – Live in Ballroom 1 & 2 – Live Stream in Ballroom 3 & 4 Innovating Hepatocellular Carcinoma Surveillance with Biomarker-based Algorithm Prof. Henry Chan View Bio |
|
| Session 6: Consensus Statement 5: Diagnosis And Management Of ALT Flares ALT flares Chairs: Prof. Ed Gane View Bio & Dr. Edhel Tripon |
|
| a. Definitions of ALT flares and natural history and prediction of decompensation Prof. Teerha Piratvisuth View Bio |
|
| b. ALT flares associated with novel therapies: risks and benefits Prof. MF Yuen View Bio |
|
| c. Management of ALT flares, beyond antiviral therapy pros and cons Prof. Lim Seng Gee View Bio |
|
| d. Discussion | |
| Lunch symposium sponsored by GSK – Live in Ballroom 3 & 4 – Live Stream in Ballroom 1 & 2 Destination functional cure in CHB: What success looks like? |
|
| a. Welcome and Introduction Prof. Lim Seng Gee View Bio |
|
| b. Lighting the road ahead: Understanding the burden of CHB & importance of Functional cure Prof. Lim Seng Gee View Bio |
|
| c. Vital components of Functional Cure – Targeting DNA, reducing HBsAg, and stimulating the immune system Prof. Man Fung Yuen View Bio |
|
| d. Navigating the path forward: Old and new strategies to achieve Functional Cure Prof. Edward Gane View Bio |
|
| Session 7: Delta Hepatitis: Consensus Statement 6: Chair: Prof. Khin Maung Win & Prof. Norah Terrault View Bio |
|
| (1) The burden of HDV in Asia and endpoints of Delta cure | |
| a. Delta natural history Prof. Junqi Niu View Bio |
|
| b. Asian epidemiology and diagnosis of Delta infection Prof. Saeed Hamid View Bio |
|
| (2) Delta Hepatitis endpoints (Con’t) | |
| a. HBV and HDV biomarkers for Delta management Prof. Pietro Lampertico View Bio |
|
| b. What is the appropriate endpoints for Delta cure Prof. Geoff Dusheiko View Bio |
|
| c. Discussion | |
| Session 8: Delta Hepatitis existing and emerging therapy Consensus Statement 7: Management Of HDV In Asia Chair: Prof. Wei Lai View Bio & Prof. Norah Terrault View Bio |
|
| a. Bulevirtide (BLV) monotherapy or in combination Prof. Pietro Lampertico View Bio |
|
| b. Other Anti HDV therapeutics: current and novel therapies Prof. Saeed Hamid View Bio |
|
| c. Discussion | |
| End of Day 2 | |
August, 2025
24
| Programme | Time (SGT) |
|---|---|
| Session 9: Consensus Statement Session (Closed Door Meeting) In Ballroom 1 Chair: Prof. Lim Seng Gee View Bio |
|
| Tea Break | |
| a. Charting the path to HCV elimination in South East Asia – overview of national plans, screening targets, integration into primary care towards WHO 2030 goal Dr. John Ward View Bio |
|
| b. From diagnosis to cure: scale up test and treat and practical models to decentralise HCV care Prof. Philippa Easterbrook View Bio |
|
| c. Closing the gaps: Advancing Singapore towards HCV elimination Prof. Wong Chen Seong View Bio |
|
| d. Q&A | |
| Session 10: HBV/HDV Elimination Forum Chair: Prof. Saeed Hamid View Bio & Prof. Philippa Easterbrook View Bio |
|
| HBV elimination: The greatest achievement,. The greatest challenge Dr. John Ward View Bio |
|
| What practical steps can we take to achieve WHO 2030 goals Prof. Philippa Easterbrook (UCL London) View Bio |
|
| What is the status, challenges and solutions for HDV elimination in Asia Prof. Saeed Hamid View Bio |
|
| Tea break | |
| The role of global collaboration, Trials, and stakeholders How can NGOs support the mission of HBV/HDV elimination Prof. Veronica Miller View Bio |
|
| Close of Day 3 and Conference | |